Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia
Marc Fakhoury
Molecular Neurobiology (2016) Vol. 54, Iss. 1, pp. 768-778
Closed Access | Times Cited: 70

Showing 1-25 of 70 citing articles:

Cannabidiol (CBD) use in psychiatric disorders: A systematic review
Stefania Bonaccorso, A Ricciardi, Caroline Zangani, et al.
NeuroToxicology (2019) Vol. 74, pp. 282-298
Open Access | Times Cited: 142
Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis
Deepak Cyril D’Souza, Marta Di Forti, Suhas Ganesh, et al.
The World Journal of Biological Psychiatry (2022) Vol. 23, Iss. 10, pp. 719-742
Closed Access | Times Cited: 63
The endocannabinoidome as a substrate for noneuphoric phytocannabinoid action and gut microbiome dysfunction in neuropsychiatric disorders
Vincenzo Di Marzo
Dialogues in Clinical Neuroscience (2020) Vol. 22, Iss. 3, pp. 259-269
Open Access | Times Cited: 62
Pregnenolone blocks cannabinoid-induced acute psychotic-like states in mice
Arnau Busquets‐Garcia, Edgar Soria‐Gómez, Bastien Redon, et al.
Molecular Psychiatry (2017) Vol. 22, Iss. 11, pp. 1594-1603
Open Access | Times Cited: 57
The Current and Potential Application of Medicinal Cannabis Products in Dentistry
Henry Lowe, Ngeh J. Toyang, Blair Steele, et al.
Dentistry Journal (2021) Vol. 9, Iss. 9, pp. 106-106
Open Access | Times Cited: 33
A systematic review of phytocannabinoid exposure on the endocannabinoid system: Implications for psychosis
Maya R. Jacobson, Jeremy J. Watts, Isabelle Boileau, et al.
European Neuropsychopharmacology (2019) Vol. 29, Iss. 3, pp. 330-348
Closed Access | Times Cited: 39
Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial
Anahita Salehi, Parsa Namaei, Fateme Taghavizanjani, et al.
Psychiatry Research (2022) Vol. 316, pp. 114737-114737
Closed Access | Times Cited: 20
Targeting the Gut–Brain Axis with Plant-Derived Essential Oils: Phytocannabinoids and Beyond
Luca Camarda, Laura Mattioli, Ivan Corazza, et al.
Nutrients (2025) Vol. 17, Iss. 9, pp. 1578-1578
Open Access
Could cannabidiol be used as an alternative to antipsychotics?
Marc Fakhoury
Journal of Psychiatric Research (2016) Vol. 80, pp. 14-21
Closed Access | Times Cited: 34
Cannabinoid signalling in embryonic and adult neurogenesis: possible implications for psychiatric and neurological disorders
Rúbia Maria Weffort de Oliveira, Cilene Lino de Oliveira, Francisco Silveira Guimarães, et al.
Acta Neuropsychiatrica (2018) Vol. 31, Iss. 1, pp. 1-16
Open Access | Times Cited: 33
Role of N-Arachidonoyl-Serotonin (AA-5-HT) in Sleep-Wake Cycle Architecture, Sleep Homeostasis, and Neurotransmitters Regulation
Eric Murillo‐Rodríguez, Vincenzo Di Marzo, Sérgio Machado, et al.
Frontiers in Molecular Neuroscience (2017) Vol. 10
Open Access | Times Cited: 30
Decreased CB receptor binding and cannabinoid signaling in three brain regions of a rat model of schizophrenia
Edina Szűcs, Szabolcs Dvorácskó, Csaba Tömböly, et al.
Neuroscience Letters (2016) Vol. 633, pp. 87-93
Closed Access | Times Cited: 27
Endocannabinoid system imbalance in the postmortem prefrontal cortex of subjects with schizophrenia
Carolina Muguruza, Benito Morentín, J. Javier Meana, et al.
Journal of Psychopharmacology (2019) Vol. 33, Iss. 9, pp. 1132-1140
Closed Access | Times Cited: 26
Cannabidiol for the treatment of psychosis among patients with schizophrenia and other primary psychotic disorders: A systematic review with a risk of bias assessment
Maykel F. Ghabrash, Stephanie Coronado‐Montoya, John Aoun, et al.
Psychiatry Research (2020) Vol. 286, pp. 112890-112890
Closed Access | Times Cited: 25
Are CB2 Receptors a New Target for Schizophrenia Treatment?
Isadora Lopes Cortez, Naielly Rodrigues da Silva, Francisco Silveira Guimarães, et al.
Frontiers in Psychiatry (2020) Vol. 11
Open Access | Times Cited: 24
Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders?
Cássio Morais Loss, Lucas Teodoro, Gabriela Doná Rodrigues, et al.
Frontiers in Pharmacology (2021) Vol. 11
Open Access | Times Cited: 23
Endocannabinoids and cortical plasticity: CB1R as a possible regulator of the excitation/inhibition balance in health and disease
Lucas J. A. Durieux, Sara R. J. Gilissen, Lut Arckens
European Journal of Neuroscience (2021) Vol. 55, Iss. 4, pp. 971-988
Open Access | Times Cited: 22
Cannabinoid control of hippocampal functions: the where matters
Almudena Robledo‐Menendez, Maria Vella, Pedro Grandes, et al.
FEBS Journal (2021) Vol. 289, Iss. 8, pp. 2162-2175
Open Access | Times Cited: 22
Cannabinoid CB2 Receptors in Neurodegenerative Proteinopathies: New Insights and Therapeutic Potential
Barbara Vuić, Tina Milos, Lucija Tudor, et al.
Biomedicines (2022) Vol. 10, Iss. 12, pp. 3000-3000
Open Access | Times Cited: 16
The Endocannabinoid System May Modulate Sleep Disorders in Aging
Eric Murillo‐Rodríguez, Henning Budde, André Barciela Veras, et al.
Current Neuropharmacology (2019) Vol. 18, Iss. 2, pp. 97-108
Open Access | Times Cited: 24
CB1 allosteric modulators and their therapeutic potential in CNS disorders
Catharine A. Mielnik, Vincent Lam, Ruth A. Ross
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2020) Vol. 106, pp. 110163-110163
Closed Access | Times Cited: 21
Gene-environment interaction between an endocannabinoid system genetic polymorphism and cannabis use in first episode of psychosis
Miquel Bioque, Sergi Mas, Maria C. Costanzo, et al.
European Neuropsychopharmacology (2019) Vol. 29, Iss. 6, pp. 786-794
Closed Access | Times Cited: 20
Role of the endocannabinoid and endovanilloid systems in an animal model of schizophrenia-related emotional processing/cognitive deficit
Valéria de Almeida, Raquel Levin, Fernanda Fiel Peres, et al.
Neuropharmacology (2019) Vol. 155, pp. 44-53
Closed Access | Times Cited: 20
Progress in Genetic Polymorphisms Related to Lipid Disturbances Induced by Atypical Antipsychotic Drugs
Nana Li, Ting Cao, Xiangxin Wu, et al.
Frontiers in Pharmacology (2020) Vol. 10
Open Access | Times Cited: 19
HU-910, a CB2 receptor agonist, reverses behavioral changes in pharmacological rodent models for schizophrenia
Isadora Lopes Cortez, Nicole Rodrigues da Silva, Nicole Rodrigues da Silva, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2022) Vol. 117, pp. 110553-110553
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top